Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESOLVE: Tremelimumab + Durvalumab + Belinostat in Urothelial Carcinoma
NCT05154994Phase 1Completed
- Sponsor
- University of Utah
- Start
- Jan 2022
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of belinostat in urothelial carcinoma (UC), sponsored by University of Utah. Primary endpoints: Dose Limiting Toxicities at 21 days and Adverse Events at 3 years. Started Jan 2022; status: completed.
02
Drugs
belinostat
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05154994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05154994.